Retatrutide phase 2 trial data in type 2 diabetes have generated considerable clinical interest, with weight loss percentages and glycaemic improvements exceeding those seen with many existing therapies. Retatrutide (LY3437943), developed by Eli Lilly, is an investigational once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 results published in The Lancet (2023) demonstrated dose-dependent body weight reductions of up to approximately 16.9% and meaningful HbA1c improvements at 24 weeks in adults with type 2 diabetes. This article summarises the key findings, safety data, and current development status.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, targeting appetite, glucose metabolism, and energy expenditure through a single agent.

Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly and Company. It belongs to a novel class of agents known as triple agonists, designed to simultaneously activate three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism of action distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist).

The GLP-1 component promotes insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite — effects well established across the GLP-1 drug class. GIP receptor agonism is hypothesised, based on preclinical and early clinical data, to complement GLP-1 effects on insulin secretion and may influence adipose tissue metabolism, though the precise contribution in humans remains an area of active investigation.

The addition of glucagon receptor agonism is a key distinguishing feature of the tri-agonist design. Glucagon receptor activation is thought to increase energy expenditure and promote hepatic fat oxidation, potentially contributing to the substantial weight loss observed in early trials. However, glucagon also raises hepatic glucose output, which could be counterproductive in type 2 diabetes; the tri-agonist design relies on the GLP-1 and GIP components to offset this hyperglycaemic potential. These mechanistic interactions are supported by preclinical and early-phase human data, and their relative contributions in clinical practice continue to be studied.

By engaging all three receptors, retatrutide targets multiple pathways involved in energy homeostasis, appetite regulation, and glucose metabolism simultaneously. This multi-receptor approach is hypothesised to produce additive or synergistic effects on both body weight and glycaemic control. It is administered as a subcutaneous injection, consistent with other agents in this therapeutic class. The mechanistic rationale is described in the phase 2 publications by Rosenstock et al. (The Lancet, 2023) and Jastreboff et al. (New England Journal of Medicine, 2023).

Phase 2 Trial Results: Weight Loss Outcomes in Type 2 Diabetes

At the highest 12 mg dose, adults with type 2 diabetes achieved approximately 16.9% mean body weight reduction from baseline at 24 weeks in a randomised, placebo-controlled phase 2 trial published in The Lancet (2023).

Phase 2 data for retatrutide in adults with type 2 diabetes were published by Rosenstock et al. in The Lancet in 2023. The randomised, double-blind, placebo-controlled trial enrolled adults with type 2 diabetes managed with diet and exercise alone or with stable oral antidiabetic therapy (excluding sulphonylureas and insulin in most arms). Participants received once-weekly subcutaneous injections of retatrutide at doses of 0.5 mg, 4 mg, 8 mg, or 12 mg, or placebo, over a 24-week treatment period, with gradual dose escalation to the target maintenance dose.

Weight loss results were observed across all active dose groups in a dose-dependent pattern. At the highest dose of 12 mg, participants with type 2 diabetes achieved a mean body weight reduction of approximately 16.9% from baseline at 24 weeks. At the 8 mg dose, mean weight loss was approximately 13.3%. Lower doses produced more modest reductions:

• 4 mg dose: approximately 8.7% mean weight reduction

• 0.5 mg dose: approximately 2.0% mean weight reduction

• Placebo: a small mean weight gain of approximately 2.0%

Readers should note that these figures are drawn from a single phase 2 trial with a relatively small sample size and 24-week duration; they should not be directly compared with results from trials of other agents, as differences in trial design, population, background therapy, and follow-up duration make cross-trial comparisons unreliable.

Nonetheless, the magnitude of weight reduction observed at higher doses is notable given that achieving substantial weight loss in individuals with type 2 diabetes has historically been more difficult than in those with obesity alone, partly due to the metabolic effects of the condition itself and certain antidiabetic medications. These findings support further evaluation in the ongoing phase 3 programme. Readers are encouraged to consult the primary publication (Rosenstock et al., The Lancet, 2023) and the ClinicalTrials.gov record for full participant numbers, confidence intervals, and protocol details.

Blood Glucose and HbA1c Changes Observed in the Trial

The 12 mg dose produced mean HbA1c reductions of approximately 2.2 percentage points (~24 mmol/mol) at 24 weeks, with some participants reaching HbA1c levels below the 48 mmol/mol diagnostic threshold for type 2 diabetes.

Beyond weight reduction, the phase 2 trial demonstrated improvements in glycaemic control across all active dose groups. HbA1c — the standard long-term marker of blood glucose management, reported in the UK in mmol/mol — fell in participants receiving retatrutide compared with placebo. At the 12 mg dose, mean HbA1c reductions from baseline reached approximately 2.2 percentage points (around 24 mmol/mol) at 24 weeks. At the 8 mg dose, reductions were approximately 1.8 percentage points, and the 4 mg dose produced reductions of around 1.1 percentage points.

A notable proportion of participants in the higher-dose groups achieved HbA1c levels below 48 mmol/mol (6.5%) — the diagnostic threshold for type 2 diabetes in the UK — and some reached levels at or below 42 mmol/mol (6.0%), which falls within the range of non-diabetic hyperglycaemia as defined by UK and WHO criteria. These findings suggest the potential for substantial glycaemic improvement in certain individuals, though results from a single phase 2 trial should be interpreted cautiously. NICE NG28 emphasises that HbA1c targets should be individualised, taking into account patient preferences, comorbidities, and risk of hypoglycaemia, rather than applying a single universal threshold.

Fasting serum glucose levels also fell across active treatment arms, with the greatest reductions at the 12 mg dose. The glycaemic benefits are likely multifactorial, reflecting both the direct insulinotropic and glucagonostatic effects of the GLP-1 and GIP receptor components and the indirect benefits of weight reduction.

No episodes of severe hypoglycaemia were reported in participants not using sulphonylureas or insulin; the trial design largely excluded these agents, which is an important consideration when interpreting the hypoglycaemia data.

Clinicians and patients should also be aware that rapid, large reductions in HbA1c — as may occur with potent glucose-lowering therapies — can occasionally be associated with transient worsening of diabetic retinopathy. Patients should continue to attend their scheduled NHS Diabetic Eye Screening Programme appointments and report any changes in vision to their healthcare team promptly.

Side Effects and Safety Data from Phase 2 Studies

The most common adverse effects were gastrointestinal — particularly nausea — and were generally mild to moderate; a dose-dependent heart rate increase was also observed, consistent with incretin-class effects.

The safety and tolerability profile of retatrutide observed in the phase 2 trial was broadly consistent with that of other incretin-based therapies, including GLP-1 receptor agonists. The most frequently reported adverse effects were gastrointestinal in nature, generally mild to moderate in severity and transient, typically occurring during the dose-escalation period.

Commonly reported side effects included:

• Nausea (the most frequently reported, particularly at higher doses)

• Vomiting

• Diarrhoea

• Decreased appetite

• Constipation

• Eructation (belching)

At the 12 mg dose, gastrointestinal adverse events were reported in a higher proportion of participants compared with lower doses, though most did not lead to treatment discontinuation. Gradual dose escalation — a strategy already employed with approved agents such as semaglutide and tirzepatide — appeared to support tolerability.

A dose-dependent increase in heart rate was observed with retatrutide. This effect has been noted with GLP-1 receptor agonists as a class and may be further influenced by glucagon receptor agonism; the precise contribution of each receptor component in humans requires further study. This finding warrants careful monitoring in future larger trials, particularly in individuals with pre-existing cardiovascular conditions.

As with other agents that cause significant weight loss or gastrointestinal fluid losses, there are theoretical class-related risks that warrant attention, including gallbladder disease (cholelithiasis and cholecystitis have been reported with GLP-1 receptor agonists), and dehydration or acute kidney injury in the context of persistent vomiting or diarrhoea. Injection-site reactions and hypersensitivity responses are also possible with subcutaneous injectable therapies.

It is important to note that no signal for pancreatitis, significant hepatic enzyme elevation, or thyroid C-cell pathology was observed in the phase 2 data; however, the trial duration (24 weeks) and sample size were insufficient to detect or exclude rare adverse events. These areas will require evaluation in the larger, longer phase 3 programme.

As retatrutide remains investigational, its full long-term safety profile has not been established. Anyone participating in a clinical trial who experiences persistent or severe gastrointestinal symptoms, unexplained abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of dehydration, or other concerning symptoms should contact their supervising healthcare team promptly. Suspected adverse reactions to medicines — including those encountered in clinical trials — can be reported in the UK via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Current Development Status and Availability Outlook

Retatrutide has no MHRA or EMA marketing authorisation and is not available outside clinical trials; phase 3 studies are ongoing, and NICE appraisal would be required before NHS availability.

As of the time of writing, retatrutide remains an investigational medicine and has not received marketing authorisation from any regulatory body, including the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom or the European Medicines Agency (EMA). It is therefore not available for prescription outside of authorised clinical trials. Patients should not attempt to obtain retatrutide or any other unlicensed injectable medicine through online or unregulated sources, as the safety, quality, and authenticity of such products cannot be assured.

Following the phase 2 results published in 2023, Eli Lilly has progressed retatrutide into phase 3 clinical development. A phase 3 programme evaluating retatrutide across multiple populations — including adults with obesity, adults with type 2 diabetes, and individuals with obesity-related comorbidities — is under way. Readers can verify the current status, naming, and scope of these trials via ClinicalTrials.gov, where registered study records and NCT identifiers are publicly available. The MHRA and EMA websites also provide up-to-date information on the regulatory status of investigational medicines.

Any regulatory submission to the MHRA or EMA would be contingent on the outcomes of the phase 3 programme and subsequent regulatory review; no specific timelines can be stated with certainty at this stage. Should marketing authorisation be granted, NICE would subsequently need to evaluate retatrutide for clinical and cost-effectiveness before it could be routinely commissioned on the NHS — a process that typically follows initial regulatory approval.

For patients with type 2 diabetes or obesity, it is important to discuss current evidence-based treatment options with a GP or specialist. Existing NICE-approved therapies, including semaglutide and tirzepatide, already offer substantial benefits for eligible patients and are available through NHS pathways. Clinicians and patients wishing to follow retatrutide's development are encouraged to monitor updates via the MHRA, EMA, ClinicalTrials.gov, and peer-reviewed clinical literature as phase 3 data emerge.

Frequently Asked Questions